Celularity

CELU · NASDAQ

$1.26+$0.10 (+8.62%)TodayMarket closed ·
Prev close $1.16

Key indicators

CELU profitability and balance sheet ratios

EPS -$0.8562 in Q4 FY25, against -$0.5963 a year earlier.

EPS by quarter
PeriodEPS
Q1 FY24-$1.05
Q2 FY24-$0.295
Q3 FY24-$0.7273
Q4 FY24-$0.5963
Q1 FY25-$0.8395
Q2 FY25-$1.02
Q3 FY25-$0.8758
Q4 FY25-$0.8562

Where the money went

Q1 FY26, from revenue to net income

Celularity brought in $3.8M of revenue in Q1 FY26, −66.3% on a year earlier. 18¢ of every dollar became profit.

Revenue
$3.8M
Costs, expenses and taxes
$3.2M
Net income
$0.7M
Net margin
17.6%

Income statement

Revenue and profit by reporting period

Revenue
Net income
CELU income statement, quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26
Revenue$5.3M$4.1M$3.8M
Gross profit$1.4M−$3.3M$2.4M
Operating income−$12.9M−$22.1M−$10.1M
Net income−$23.1M−$24.4M$0.7M
Diluted EPS-$0.88-$0.86$0.02

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
CELU balance sheet, quarterly
Line itemJun 2025Sep 2025Dec 2025
Total assets$120.3M$114.2M$107.3M
Total liabilities$145.8M$134.3M$145.4M
Shareholder equity−$25.5M−$20.1M−$38.1M
Cash and short-term investments$0.9M$0.1M$6.2M
Total debt$43.4M$40.0M$47.8M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
CELU cash flow, quarterly
Line itemQ3 FY25Q4 FY25Q1 FY26
Operating cash flow−$4.2M−$5.1M$1.4M
Investing cash flow$0.0M$0.0M$0.0M
Financing cash flow$3.5M$11.2M−$7.3M
Capital expenditure$0.0M$0.0M$0.0M
Free cash flow−$4.2M−$5.1M$1.4M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.